FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel; ...
Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Hello, everyone, and welcome to our third quarter 2024 results call. This event is being recorded. Our speakers today will be our CEO, ...
As of September 30, 2024, Núcleo's subscriber base totaled 2.5 million. Of the total number of accesses, 74% correspond to prepaid plans and 26% to postpaid plans, whereas as of September 30, 2023, ...